Metabolic reprogramming signature predicts immunotherapy efficacy in lung adenocarcinoma: Targeting SLC25A1 to overcome immune resistance
摘要: Objective: Lung adenocarcinoma(LUAD) is the most common subtype of lung cancer. Despite significant advances in immunotherapy, treatment responses vary substantially among individuals. Metab... ...
(共20页)
开通会员,享受整站包年服务